This is a StreetInsider.com Premium Only Page

Celsion (CLSN) – StreetInsider.com Reports

Sep 19, 2022 04:30 PM Celsion (CLSN) Announces Name Change to Imunon, Inc

Aug 15, 2022 08:02 AM Celsion (CLSN) Reports Smaller Q2 Loss

Jul 19, 2022 08:30 AM Celsion (CLSN) Appoints Corinne Le Goff as President and CEO

Apr 21, 2022 11:32 AM Celsion (CLSN) Highlights PLACCINE Vaccine Platform Technology

Apr 13, 2022 06:27 AM UPDATE: H.C. Wainwright Starts Celsion Corp (CLSN) at Buy

Apr 6, 2022 08:31 AM Celsion (CLSN) Prices Direct 1.33M Share Offering at $5.27/sh

Feb 28, 2022 09:01 AM Celsion (CLSN) Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

Feb 28, 2022 08:31 AM Celsion (CLSN) Announces Stock Consolidation

Feb 23, 2022 09:44 AM Dawson James Reiterates Neutral Rating on Celsion Corp (CLSN), Believes GEN-1's Probability of Success is Only 10%

Feb 17, 2022 08:35 AM Celsion (CLSN) Announces Data Safety Monitoring Board Recommends to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1

Jan 31, 2022 08:09 AM Celsion (CLSN) Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Jan 13, 2022 05:31 PM Celsion (CLSN) Prices $30M Direct Convertible Redeemable Preferred Stock Offering

Jan 11, 2022 05:20 AM Celsion (CLSN) Prices $30M Direct Convertible Redeemable Preferred Stock Offering

Sep 17, 2021 09:01 AM Celsion (CLSN), Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine

Aug 12, 2021 04:47 PM Celsion Corp (CLSN) PT Lowered to $3 at Brookline Capital Markets, Following Earnings

Jul 19, 2021 08:11 AM Celsion (CLSN) Reports DSMB Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Jul 15, 2021 08:02 AM Celsion (CLSN) Appoints Dan H. Barouch and Luke D. Handke to Vaccine Advisory Board

Jun 9, 2021 08:01 AM Celsion (CLSN) Adds Christine A. Pellizzari to Board

Jun 8, 2021 08:10 AM Celsion (CLSN) Appoints Stacy R. Lindborg, Ph.D. to Board

Apr 1, 2021 08:34 AM Poster on Celsion Corporation’s (CLSN) Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Mar 31, 2021 09:22 AM Pre-Open Stock Movers 03/31: (SURF) (CHWY) (CASI) Higher; (DCTH) (RMO) (CLSN) Lower (more...)

Mar 31, 2021 08:03 AM Celsion (CLSN) Reports 11.538M Share Registered Direct Offering at $1.30/Sh

Feb 25, 2021 08:46 AM Celsion Corporation (CLSN) Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Feb 22, 2021 12:26 PM Celsion Corp (CLSN) PT Raised to $4 at Brookline Capital Markets, Following Clinical Update

Feb 22, 2021 09:27 AM Pre-Open Stock Movers 02/22: (CLSN) (CTB) (CCIV) Higher; (OTIC) (EBIX) (PBR) Lower (more...)

Feb 22, 2021 07:30 AM Celsion (CLSN) Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer

Feb 12, 2021 08:32 AM Celsion (CLSN) Announces Formation of Vaccine Advisory Board

Feb 11, 2021 08:44 AM Celsion (CLSN) Issues Letter to Stockholders

Jan 28, 2021 08:07 AM Celsion (CLSN) Files Provisional U.S. Patent Application for a Broad Range of Next Generation DNA Vaccines

Jan 22, 2021 08:41 AM Celsion (CLSN) announces $35 million registered direct offering of common stock

Oct 12, 2020 08:08 AM Celsion (CLSN) Issues Letter to Stockholders

Oct 7, 2020 04:18 PM Horizon Technology Finance (HRZN) Provides Q3 Portfolio Update

Sep 8, 2020 08:37 AM Celsion (CLSN) Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study

Jul 27, 2020 08:33 AM Celsion (CLSN) Begins Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer

Jul 16, 2020 04:12 AM Oppenheimer Downgrades Celsion Corp (CLSN) to Perform

Jul 15, 2020 02:29 PM Celsion Corp (CLSN) PT Lowered to $4 at Brookline Capital Markets

Jul 14, 2020 07:29 AM Dawson James Downgrades Celsion Corp (CLSN) to Neutral

Jul 13, 2020 10:46 AM Dawson James Downgrades Celsion Corp (CLSN) to Hold

Jul 13, 2020 09:31 AM Pre-Open Stock Movers 07/13: (BFYT) (ALT) (TSLA) Higher; (CLSN) Lower (more...)

Jul 13, 2020 08:32 AM Celsion (CLSN) Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study

Jun 25, 2020 11:40 AM Celsion Corp (CLSN) PT Raised to $5 at Dawson James

Jun 25, 2020 08:01 AM Celsion (CLSN) Confirms Launch of Second Interim Analysis of Ph. 3 OPTIMA Study of ThermoDox in Primary Liver Cancer

Jun 22, 2020 03:01 PM Celsion (CLSN) Prices 2.67M Share Common Stock Offering at $3.75/sh

May 29, 2020 08:33 AM Celsion (CLSN) Announces Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer

Apr 15, 2020 08:34 AM Celsion (CLSN) Reports that Sufficient Events Have Been Reached for Second Interim Analysis of Phase III OPTIMA Study of ThermoDox in Primary Liver Cancer

Mar 23, 2020 08:15 AM Celsion (CLSN) Reports GEN-1 Immunotherapy Granted Orphan Drug Designation from European Medicines Agency

Mar 19, 2020 08:07 AM Celsion (CLSN) Reports Encouraging Initial Clinical Results from Phase I Portion of Phase I/II OVATION 2 Study

Feb 28, 2020 08:45 AM Celsion (CLSN) Prices $4.8 Million Registered Direct Offering of Common Stock, Warrants

Feb 6, 2020 09:40 AM Celsion (CLSN) Reports DSMB Confirms Initial Safety of Weekly GEN-1 Dosing at 100 mg/m2 in 15 Randomized Patients with Advanced Ovarian Cancer

Nov 14, 2019 08:02 AM Celsion (CLSN) Announces Publication of Research on Fluorescence Imaging of ThermoDox Uptake in International Journal of Hyperthermia